Carcinoembryonic antigen (CEA) is primarily used as a biomarker for colorectal cancer, with levels ranging from 5 to 10 μg/L, but it can also be elevated in other cancers, such as breast, lung, and pancreatic cancers. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.